A Phase 3 interventional study of REL-1017 in Major Depressive Disorder, sponsored by Relmada Therapeutics, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by Relmada Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 96th largest by enrollment of the 1,323 interventional ones that give a count, is one of 72 that started in 2021, is one of 240 in phase 3, and was the 1,121st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 72 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 627 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Relmada Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Relmada Therapeutics, Inc. has 5 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a 1-year, multicenter, open-label, long-term study to assess the safety of REL-1017 once daily (QD) as monotherapy or as adjunctive treatment of Major Depressive Disorder. Adjunctive study participants continued to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.
This was a multicenter, open-label, long-term study of REL-1017 to evaluate the long-term safety and long-term durability of response in patients with MDD. Patients who completed previous randomized, double-blind Phase 3 trials (NCT04688164, NCT04855747, NCT05081167) of REL-1017 as adjunctive therapy or monotherapy for MDD were asked to continue treatment with REL-1017 25 mg daily for up to 1 year. De novo patients who satisfied inclusion/exclusion criteria also were enrolled and received a 75 mg loading dose of REL-1017 on Day 1 followed by a maintenance dose of 25 mg REL-1017 daily for the remainder of the study (Days 2-365). When REL-1017 was administered as adjunctive treatment, patients continued to use a stable dosage of their concomitant antidepressants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roll-over participants received 25 mg REL-1017 (one 25 mg REL-1017 tablet), orally, per day, either as a monotherapy or in addition to their ongoing antidepressant (ADT), rolling over from the monotherapy study REL-1017-303 or the adjunctive therapy studies REL-1017-301 and REL-1017-302, respectively. De Novo participants received a 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) on Day-1 of the 365-day treatment period. From Day-2 to Day-365, participants received 25 mg REL-1017 either as monotherapy or as adjunctive therapy.
Drug: REL-1017
REL-1017 tablet
Also known as: Esmethadone HCl
Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs)
Subjects with at least one Treatment Emergent Adverse Events (TEAEs)
Time frame: 52 weeks
Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 3
Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 3. A negative change from baseline indicates shortening of the QTcF.
Time frame: 3 Month
Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 6
Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 6. A negative change from baseline indicates shortening of the QTcF.
Time frame: 6 Month
Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 12
Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 12. A negative change from baseline indicates shortening of the QTcF.
Time frame: 12 Month
Change in Diastolic Blood Pressure From Baseline to Month 3
Cardiac Safety of REL-1017 as measured by the Diastolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 3. A negative change from baseline indicates a reduction in Diastolic Blood Pressure.
Time frame: 3 Month
Change in Diastolic Blood Pressure From Baseline to Month 12
Cardiac Safety of REL-1017 as measured by the Diastolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 12. A negative change from baseline indicates a reduction in Diastolic Blood Pressure.
Time frame: 12 Month
Change in Systolic Blood Pressure From Baseline to Month 3
Cardiac Safety of REL-1017 as measured by the Systolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 3. A negative change from baseline indicates a reduction in Systolic Blood Pressure.
Time frame: 3 Month
Change in Systolic Blood Pressure From Baseline to Month 12
Cardiac Safety of REL-1017 as measured by the Systolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 12. A negative change from baseline indicates a reduction in Systolic Blood Pressure.
Time frame: 12 Month
Change in Heart Rate From Baseline to Month 3
Cardiac Safety of REL-1017 as measured by the Heart Rate (Supine/Semi-Supine) From Baseline to Month 3. A negative change from baseline indicates a reduction in Heart Rate.
Time frame: 3 Month
Change in Heart Rate From Baseline to Month 12
Cardiac Safety of REL-1017 as measured by the Heart Rate (Supine/Semi-Supine) From Baseline to Month 12. A negative change from baseline indicates a reduction in Heart Rate.
Time frame: 12 Month
Change in Weight From Baseline to Month 3
Overall Safety of REL-1017 as measured by Weight From Baseline to Month 3. A negative change from baseline indicates a reduction in Weight.
Time frame: 3 Month
Change in Weight From Baseline to Month 12
Overall Safety of REL-1017 as measured by Weight From Baseline to Month 12. A negative change from baseline indicates a reduction in Weight.
Time frame: 12 Month
Change in the MADRS10 Total Score From Baseline to Month 3
Therapeutic efficacy of REL-1017 in the Montgomery-Asberg Depression Rating Scale (MADRS10) A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. A negative change from baseline indicates improvement.
Time frame: 3 Month
Change in the MADRS10 Total Score From Baseline to Month 12
Therapeutic efficacy of REL-1017 in the Montgomery-Asberg Depression Rating Scale (MADRS10) A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. A negative change from baseline indicates improvement.
Time frame: 12 Month
| Milestone | REL-1017 |
|---|---|
| Started | 627 |
| Dosed | 624 |
| Completed | 182 |
| Not completed | 445 |
| Withdrew: Adverse event | 21 |
| Withdrew: Withdrawal by subject | 116 |
| Withdrew: Lack of efficacy | 21 |
| Withdrew: Lost to follow-up | 49 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Physician decision | 5 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Non-compliance with study drug | 11 |
| Withdrew: Non-compliance with study schedule | 4 |
| Withdrew: Study completed by sponsor | 202 |
| Withdrew: Other | 13 |
Subjects with at least one Treatment Emergent Adverse Events (TEAEs)
| participants | REL-1017 |
|---|---|
| Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs) | 350 |
Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 3. A negative change from baseline indicates shortening of the QTcF.
| ms | REL-1017 |
|---|---|
| Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 3 | 4.11 ± 14.54 |
Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 6. A negative change from baseline indicates shortening of the QTcF.
| ms | REL-1017 |
|---|---|
| Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 6 | 2.70 ± 15.26 |
Cardiac Safety of REL-1017 as measured by the Change in the QT interval with Fridericia's correction (QTcF) Interval From Baseline to Month 12. A negative change from baseline indicates shortening of the QTcF.
| ms | REL-1017 |
|---|---|
| Change in the QT Interval With Fridericia's Correction (QTcF) Interval From Baseline to Month 12 | 2.59 ± 13.77 |
Cardiac Safety of REL-1017 as measured by the Diastolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 3. A negative change from baseline indicates a reduction in Diastolic Blood Pressure.
| mmHg | REL-1017 |
|---|---|
| Change in Diastolic Blood Pressure From Baseline to Month 3 | 0.5 ± 7.3 |
Cardiac Safety of REL-1017 as measured by the Diastolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 12. A negative change from baseline indicates a reduction in Diastolic Blood Pressure.
| mmHg | REL-1017 |
|---|---|
| Change in Diastolic Blood Pressure From Baseline to Month 12 | -0.2 ± 8.4 |
Cardiac Safety of REL-1017 as measured by the Systolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 3. A negative change from baseline indicates a reduction in Systolic Blood Pressure.
| mmHg | REL-1017 |
|---|---|
| Change in Systolic Blood Pressure From Baseline to Month 3 | 0.4 ± 9.9 |
Cardiac Safety of REL-1017 as measured by the Systolic Blood Pressure (Supine/Semi-Supine) From Baseline to Month 12. A negative change from baseline indicates a reduction in Systolic Blood Pressure.
| mmHg | REL-1017 |
|---|---|
| Change in Systolic Blood Pressure From Baseline to Month 12 | 0.0 ± 10.9 |
Cardiac Safety of REL-1017 as measured by the Heart Rate (Supine/Semi-Supine) From Baseline to Month 3. A negative change from baseline indicates a reduction in Heart Rate.
| beats/min | REL-1017 |
|---|---|
| Change in Heart Rate From Baseline to Month 3 | 0.8 ± 9.2 |
Cardiac Safety of REL-1017 as measured by the Heart Rate (Supine/Semi-Supine) From Baseline to Month 12. A negative change from baseline indicates a reduction in Heart Rate.
| beats/min | REL-1017 |
|---|---|
| Change in Heart Rate From Baseline to Month 12 | -0.1 ± 9.6 |
Overall Safety of REL-1017 as measured by Weight From Baseline to Month 3. A negative change from baseline indicates a reduction in Weight.
| kg | REL-1017 |
|---|---|
| Change in Weight From Baseline to Month 3 | 0.32 ± 4.45 |
Overall Safety of REL-1017 as measured by Weight From Baseline to Month 12. A negative change from baseline indicates a reduction in Weight.
| kg | REL-1017 |
|---|---|
| Change in Weight From Baseline to Month 12 | 0.33 ± 5.56 |
Therapeutic efficacy of REL-1017 in the Montgomery-Asberg Depression Rating Scale (MADRS10) A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. A negative change from baseline indicates improvement.
| units on a scale | REL-1017 |
|---|---|
| Change in the MADRS10 Total Score From Baseline to Month 3 | -20.1 ± 10.7 |
Therapeutic efficacy of REL-1017 in the Montgomery-Asberg Depression Rating Scale (MADRS10) A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. A negative change from baseline indicates improvement.
| units on a scale | REL-1017 |
|---|---|
| Change in the MADRS10 Total Score From Baseline to Month 12 | -21.6 ± 10.4 |
Collected over A Treatment Emergent Adverse Event (TEAE) is defined as an Adverse Event (AE) that starts or worsens at any time after initiation of study drug collected up to 1 month post treatment (Day 395) as collected in the Safety Analysis Set.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REL-1017 | 0/624 (0%) | 8/624 (1.3%) | 142/624 (22.8%) |
| Event | REL-1017 |
|---|---|
| Coronary artery diseaseCardiac disorders | 1/624 |
| TachycardiaCardiac disorders | 1/624 |
| Alcohol abusePsychiatric disorders | 1/624 |
| AnxietyPsychiatric disorders | 1/624 |
| Anaphylactic reactionImmune system disorders | 1/624 |
| BacteraemiaInfections and infestations | 1/624 |
| PyelonephritisInfections and infestations | 1/624 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/624 |
| HyperreflexiaNervous system disorders | 1/624 |
| TremorNervous system disorders | 1/624 |
| Event | REL-1017 |
|---|---|
| HeadacheNervous system disorders | 61/624 |
| COVID-19Infections and infestations | 60/624 |
| Upper respiratory tract infectionsInfections and infestations | 53/624 |
Safety Analysis Set: All participants who received at least 1 dose of study drug.
| Age, Continuous(years) | REL-1017 |
|---|---|
| Mean | 42.9 ± 13.6 |
| Sex: Female, Male(Participants) | REL-1017 |
|---|---|
| Female | 433 |
| Male | 191 |
| Ethnicity (NIH/OMB)(Participants) | REL-1017 |
|---|---|
| Hispanic or Latino | 162 |
| Not Hispanic or Latino | 442 |
| Unknown or Not Reported | 20 |
| Race (NIH/OMB)(Participants) | REL-1017 |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 24 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 95 |
| White | 474 |
| More than one race | 16 |
| Unknown or Not Reported | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2021 to primary completion in Jul 2023, 27 months.
Results were first posted in Aug 2024, 1 year after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 27 months is close to that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-methadone
Relmada Therapeutics, Inc.